UPDATED: Galapagos CEO Paul Stoffels bets €225M on a new CAR-T strategy for the long suffering biotech

Paul Stoffels, Galapagos CEO (Michael Kovac/Getty Images)

June 21, 2022 04:01 PM EDTUpdated June 22, 10:54 AM

Deals

UPDATED: Galapagos CEO Paul Stoffels bets €225M on a new CAR-T strategy for the long suffering biotech

John Carroll

Editor & Founder

Tyler Patchen

News Reporter

The deeply troubled European biotech Galapagos and its new CEO Paul Stoffels are going the CAR-T route, and they have a new, €225 million buyout designed to give them an inside track over the first-gen therapies that have made their way into the market.

Just weeks after inking an exclusive licensing pact for an anti-BCMA CAR-T out of China, Dutch biotech CellPoint has struck a deal to sell the company to Galapagos, with €125 million coming in cash and another €100 million on the table for potential milestones.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Hudson, Sanofi CEO (Cyril Marcilhacy/Bloomberg via Getty Images)

June 30, 2022 07:13 AM EDTUpdated 07:26 AM

R&D

FDA+

FDA sidelines Paul Hudson's $3.7B MS drug after establishing link to liver damage

John Carroll

Editor & Founder

One of Sanofi CEO Paul Hudson’s top picks in the pipeline — picked up in a $3.7 billion buyout 2 years ago — has just been sidelined in the US by a safety issue.

The pharma giant put out word early Thursday that the FDA has put their Phase III studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold, halting enrollment and suspending dosing for patients who have been on the drug for less than 60 days. Patients who have completed at least 60 days of treatment can continue therapy as researchers explore a “limited” — but unspecified in Sanofi’s statement — number of cases of liver injury.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

July 2, 2022 06:00 AM EDT

Weekly

Pharma reacts to post-Roe; Drugmakers beef up cyber defense; Boehringer, Roche quietly axe drugs; and more

Amber Tong

Senior Editor

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

As a reminder, we are off on Monday for the Fourth of July. I hope this recap will kick off your (long) weekend well and that the rest of it will be just what you need. See you next week for a shortened edition!

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

July 1, 2022 09:43 AM EDT

#BIO22: Managing a biotech in turbulent times. 'There's a perfect shitshow out there'

John Carroll

Editor & Founder

On Tuesday, June 14, Endpoints News EIC John Carroll sat down with a group of biotech execs to discuss the bear market for industry stocks and how they were dealing with it. Here’s the conversation, which has been lightly edited for brevity.

Martin Meeson, sponsor opening:

Thank you, John. Hello everyone. My name’s Martin Meeson, I’m the CEO of Fujifilm Diosynth. For those of you who don’t know Fujifilm Diosynth, we operate in the development of clinical and commercial product scale up, we have facilities in Europe and the US, and around about 4,000 employees. We run on average about 150 programs, so when it comes to managing in turbulent times over the last two years, we’ve had quite a lot of experience of that. Not just keeping the clinical pipelines and the commercial pipelines open, but also our response to the pandemic and the molecules that we’ve had within there. One of the phrases that I coined probably about a year ago when we were talking at JP Morgan, was I talked about managing through turbulent times. Well, it’s become the fact that we are not managing and leading through these times, we are managing in them, which is why that’s really the purpose of and the topic that we’ve got today.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

ENDPOINTS CAREERS

Director of Quality Assurance

ImmunityBio

Dunkirk, NY, USA

view job offer post your job now

Eric Hughes, incoming Teva EVP of global R&D and CMO

July 1, 2022 11:13 AM EDTUpdated 11:23 AM

People

Teva chief raids Vertex for his new global head of research and development

John Carroll

Editor & Founder

Teva CEO Kåre Schultz has found his new R&D chief and CMO in Vertex’s ranks.

The global generics giant, which has some 3,500 staffers in the R&D group, has named Eric Hughes to the top research spot in the company. He’ll be replacing Hafrun Fridriksdottir, who held the role for close to five years, on Aug. 1.

Hughes hasn’t been at Vertex for long, though. He jumped from Novartis less than a year ago, after heading the immunology, hepatology & dermatology global development unit. Before that, he completed a five-year stint as head of early clinical research for the specialty discovery medicine department in the exploratory clinical & translational research group at Bristol Myers Squibb, according to his LinkedIn profile.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

Bo Cumbo, AavantiBio CEO

June 30, 2022 10:25 AM EDT

People

Cell/Gene Tx

Scoop: A small gene therapy biotech, flush with ex-Sarepta and bluebird leaders, guts CMC

Kyle LaHucik

Associate Editor

En route to entering the clinic with its first AAV-based gene therapy for a rare neuromuscular disease, AavantiBio has let go of 30 employees, Endpoints News has learned.

The move comes after a year stacking its executive bench with ex-Sarepta and bluebird bio leaders and inking multiple partnerships with the likes of Aldevron, Catalent and Resilience. The biotech also formed a scientific advisory board in February.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

June 29, 2022 02:09 PM EDTUpdated 04:01 PM

Deals

Manufacturing

Amgen sells its Turkish manufacturing arm for $135M

Tyler Patchen

News Reporter

Pharma giant Amgen has decided to sell off its Turkish manufacturing arm for nine figures.

The Eczacıbaşı Group has acquired Gensenta from the California-based pharma. The deal will see Eczacıbaşı pay $135 million for a 99.96% stake in the company. The purchase of Gensenta will be finalized after it gets approval from the Turkish Competition Authority.

According to Eczacıbaşı, Amgen Turkey will continue to keep its operations running and serve its customers.

Amgen's taking social media followers around the globe as it introduces the many different

July 1, 2022 12:47 PM EDT

Pharma

Marketing

From Tampa to Munich, Amgen’s ‘Places’ campaign introduces its locations around the world

Beth Snyder Bulik

Senior Editor

Amgen is taking social media followers around the world with its latest corporate campaign. Called “Places of Amgen,” the twice monthly posts highlight the biopharma’s different offices and sites – and the people who work there.

Each post runs on LinkedIn, Facebook and Instagram with details about the work Amgen does in that location, when it was established, comments from people who work there and other interesting facts. The most recent one about Paris, France, for example, notes that Amgen France last year signed a French association charter committed to the inclusion of LBGT+ people in the workplace.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.

ENDPOINTS CAREERS

Product Sales Manager

ImmunityBio

Remote

view job offer post your job now

On Friday, Lonza announced plans to construct a large-scale commercial drug product fill and finish facility in the town of Stein, Switzerland.

July 1, 2022 12:30 PM EDT

Financing

Manufacturing

Lonza to invest $500M+ on fill-finish facility on its home turf

Tyler Patchen

News Reporter

Lonza has been expanding its reach across the globe, bringing sites in China and the US online this year, but now they are looking closer to home for their next major investment.

The Swiss manufacturer on Friday announced plans to construct a large-scale commercial drug fill and finish facility in the town of Stein, Switzerland. The new facility will be delivered through an investment of approximately CHF 500 million, or $519 million, and is expected to be completed in 2026. The facility will also be constructed on the same campus as Lonza’s current clinical drug product facility.

Credit: Shutterstock

July 1, 2022 12:18 PM EDT

Pharma

Marketing

Biohaven takes migraine campaign to patients' Twitter feeds, months ahead of Pfizer takeover

Nicole DeFeudis

Editor

Two weeks ago, Biohaven hit an all-time high in weekly Nurtec prescriptions. CEO Vlad Coric attributes at least some of that success to a new interactive Twitter campaign that encourages patients to free their feed of potential migraine triggers.

Earlier this month, Biohaven in partnership with Twitter launched the #RelieveYourFeed campaign that allows users to customize their app settings based on their migraine triggers.